Zanidatamab zovodotin

N/A

Report date: 2025/06/24 11:24:49

Base Information

Drug NameZanidatamab zovodotin
Drug Alias NameZW-49
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsTubulin polymerisation inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesZymeworks Inc
China Registration ClassN/A

Develop Information

Active CompaniesZymeworks BC IncBeOne Medicines Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A